Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care.
Adolescent
Adult
Aged
Aged, 80 and over
Comorbidity
Dermatologic Agents
/ administration & dosage
Female
Fumarates
/ administration & dosage
Germany
/ epidemiology
Humans
Hypertension
/ epidemiology
Male
Methotrexate
/ therapeutic use
Middle Aged
Prevalence
Psoriasis
/ drug therapy
Quality of Life
Registries
Severity of Illness Index
Time Factors
Young Adult
PsoBest
fumaric acid esters
patient characteristics
psoriasis
real-world data
registry
Journal
European journal of dermatology : EJD
ISSN: 1952-4013
Titre abrégé: Eur J Dermatol
Pays: France
ID NLM: 9206420
Informations de publication
Date de publication:
01 Feb 2020
01 Feb 2020
Historique:
entrez:
7
4
2020
pubmed:
7
4
2020
medline:
20
1
2021
Statut:
ppublish
Résumé
Fumaric acid esters (FAE) represent the most widely-used oral systemic treatment for moderate-to-severe psoriasis in Germany. Not licensed outside Germany, little is known about the demographics of patients receiving FAE. PsoBest is a large national patient registry documenting long-term treatment of psoriasis in Germany. To evaluate FAE relative to methotrexate (MTX) in patients from the PsoBest registry. Patient demographics, disease severity at baseline and dosing regimen were reported for patients who initiated treatment with either FAE or MTX between 2007 and 2015. Overall, 1,409 patients treated with FAE and 877 with MTX were analysed. At baseline, compared with the MTX cohort, patients receiving FAE were younger (45.4 vs. 50.2 years; p≤0.001) and had a lower BMI (28.0 vs. 28.3 kg/m This study contributes to a better understanding of the usual practices of long-term FAE use, which may also lead to improved treatment strategies not only in Germany, but in other countries where FAE may become available in the near future.
Sections du résumé
BACKGROUND
BACKGROUND
Fumaric acid esters (FAE) represent the most widely-used oral systemic treatment for moderate-to-severe psoriasis in Germany. Not licensed outside Germany, little is known about the demographics of patients receiving FAE. PsoBest is a large national patient registry documenting long-term treatment of psoriasis in Germany.
OBJECTIVES
OBJECTIVE
To evaluate FAE relative to methotrexate (MTX) in patients from the PsoBest registry.
MATERIALS AND METHODS
METHODS
Patient demographics, disease severity at baseline and dosing regimen were reported for patients who initiated treatment with either FAE or MTX between 2007 and 2015.
RESULTS
RESULTS
Overall, 1,409 patients treated with FAE and 877 with MTX were analysed. At baseline, compared with the MTX cohort, patients receiving FAE were younger (45.4 vs. 50.2 years; p≤0.001) and had a lower BMI (28.0 vs. 28.3 kg/m
CONCLUSION
CONCLUSIONS
This study contributes to a better understanding of the usual practices of long-term FAE use, which may also lead to improved treatment strategies not only in Germany, but in other countries where FAE may become available in the near future.
Identifiants
pubmed: 32250255
pii: ejd.2020.3709
doi: 10.1684/ejd.2020.3709
doi:
Substances chimiques
Dermatologic Agents
0
Fumarates
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM